NEW YORK (

TheStreet

) --

Regeneron Pharmaceuticals

(Nasdaq:

REGN

) hit a new 52-week high Thursday as it traded at $40.35 compared with its previous 52-Week high of $40.29. Regeneron is changing hands at $40.33 with 97,014 shares traded as of 10:32 a.m. ET. Average volume has been 495,500 shares over the past 30 days.

Regeneron has a market cap of $3.5 billion and is part of the

health care

sector and

drugs

industry. Shares are up 20.3% year to date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.

  • Practice your REGN trading strategies and win cash in our stock game.

TheStreet Ratings rates Regeneron as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. You can view the full

Regeneron Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null